Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …

While prime editing enables precise sequence changes in DNA, cellular determinants of
prime editing remain poorly understood. Using pooled CRISPRi screens, we discovered that …

Infiltration of regulatory T (Treg) cells, an immunosuppressive population of CD4+ T cells,
into solid cancers represents a barrier to cancer immunotherapy. Chemokine receptors are …

Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Adoptive transfer of antigen-specific T cells represents a major advance in cancer
immunotherapy, with robust clinical outcomes in some patients. Both the number of …